8:45 AM ET
8-K
Capital Raise
Dogwood Therapeutics Capital Raise of $5M
Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.
- Value
- $5M
- Counterparty
- Sealbond Limited